vs

Side-by-side financial comparison of Better Home & Finance Holding Co (BETR) and Health Catalyst, Inc. (HCAT). Click either name above to swap in a different company.

Health Catalyst, Inc. is the larger business by last-quarter revenue ($74.7M vs $44.3M, roughly 1.7× Better Home & Finance Holding Co). Health Catalyst, Inc. runs the higher net margin — -121.9% vs -3349.0%, a 3227.1% gap on every dollar of revenue. On growth, Better Home & Finance Holding Co posted the faster year-over-year revenue change (77.4% vs -6.2%). Health Catalyst, Inc. produced more free cash flow last quarter ($9.6M vs $-167.8M). Over the past eight quarters, Better Home & Finance Holding Co's revenue compounded faster (41.1% CAGR vs -0.0%).

Bajaj Finance Limited (BFL) is an Indian deposit-taking non-banking financial company (NBFC-UL) headquartered in Pune. It has 110.64 million customers and holds assets under management worth ₹462,250 crore (US$55 billion), as of September 2025.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...

BETR vs HCAT — Head-to-Head

Bigger by revenue
HCAT
HCAT
1.7× larger
HCAT
$74.7M
$44.3M
BETR
Growing faster (revenue YoY)
BETR
BETR
+83.6% gap
BETR
77.4%
-6.2%
HCAT
Higher net margin
HCAT
HCAT
3227.1% more per $
HCAT
-121.9%
-3349.0%
BETR
More free cash flow
HCAT
HCAT
$177.4M more FCF
HCAT
$9.6M
$-167.8M
BETR
Faster 2-yr revenue CAGR
BETR
BETR
Annualised
BETR
41.1%
-0.0%
HCAT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BETR
BETR
HCAT
HCAT
Revenue
$44.3M
$74.7M
Net Profit
$-39.9M
$-91.0M
Gross Margin
Operating Margin
-3376.8%
-115.3%
Net Margin
-3349.0%
-121.9%
Revenue YoY
77.4%
-6.2%
Net Profit YoY
32.6%
-340.3%
EPS (diluted)
$-2.52
$-1.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BETR
BETR
HCAT
HCAT
Q4 25
$44.3M
$74.7M
Q3 25
$43.9M
$76.3M
Q2 25
$44.1M
$80.7M
Q1 25
$32.6M
$79.4M
Q4 24
$25.0M
$79.6M
Q3 24
$29.0M
$76.4M
Q2 24
$32.3M
$75.9M
Q1 24
$22.3M
$74.7M
Net Profit
BETR
BETR
HCAT
HCAT
Q4 25
$-39.9M
$-91.0M
Q3 25
$-39.1M
$-22.2M
Q2 25
$-36.3M
$-41.0M
Q1 25
$-50.6M
$-23.7M
Q4 24
$-59.2M
$-20.7M
Q3 24
$-54.2M
$-14.7M
Q2 24
$-41.4M
$-13.5M
Q1 24
$-51.5M
$-20.6M
Gross Margin
BETR
BETR
HCAT
HCAT
Q4 25
Q3 25
52.6%
Q2 25
Q1 25
Q4 24
Q3 24
47.5%
Q2 24
Q1 24
Operating Margin
BETR
BETR
HCAT
HCAT
Q4 25
-3376.8%
-115.3%
Q3 25
-88.9%
-22.9%
Q2 25
-81.9%
-46.0%
Q1 25
-154.9%
-25.4%
Q4 24
-1428.3%
-22.0%
Q3 24
-186.5%
-17.9%
Q2 24
-127.6%
-20.8%
Q1 24
-230.8%
-30.5%
Net Margin
BETR
BETR
HCAT
HCAT
Q4 25
-3349.0%
-121.9%
Q3 25
-89.2%
-29.1%
Q2 25
-82.2%
-50.8%
Q1 25
-155.3%
-29.9%
Q4 24
-1437.5%
-26.0%
Q3 24
-187.0%
-19.3%
Q2 24
-128.2%
-17.8%
Q1 24
-231.4%
-27.6%
EPS (diluted)
BETR
BETR
HCAT
HCAT
Q4 25
$-2.52
$-1.29
Q3 25
$-2.56
$-0.32
Q2 25
$-2.39
$-0.59
Q1 25
$-3.33
$-0.35
Q4 24
$-3.92
$-0.33
Q3 24
$-3.58
$-0.24
Q2 24
$-2.74
$-0.23
Q1 24
$-3.41
$-0.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BETR
BETR
HCAT
HCAT
Cash + ST InvestmentsLiquidity on hand
$203.4M
$95.7M
Total DebtLower is stronger
$153.3M
Stockholders' EquityBook value
$37.2M
$245.8M
Total Assets
$1.5B
$502.6M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BETR
BETR
HCAT
HCAT
Q4 25
$203.4M
$95.7M
Q3 25
$205.8M
$91.5M
Q2 25
$221.5M
$97.3M
Q1 25
$228.0M
$342.0M
Q4 24
$264.9M
$392.0M
Q3 24
$262.1M
$387.3M
Q2 24
$378.8M
$308.3M
Q1 24
$482.6M
$327.8M
Total Debt
BETR
BETR
HCAT
HCAT
Q4 25
$153.3M
Q3 25
$153.1M
Q2 25
$153.0M
Q1 25
$382.9M
Q4 24
$382.4M
Q3 24
$345.0M
Q2 24
Q1 24
Stockholders' Equity
BETR
BETR
HCAT
HCAT
Q4 25
$37.2M
$245.8M
Q3 25
$41.9M
$331.9M
Q2 25
$76.6M
$347.5M
Q1 25
$-102.1M
$376.8M
Q4 24
$-58.2M
$365.2M
Q3 24
$388.0K
$355.0M
Q2 24
$44.9M
$357.0M
Q1 24
$76.3M
$357.2M
Total Assets
BETR
BETR
HCAT
HCAT
Q4 25
$1.5B
$502.6M
Q3 25
$1.4B
$587.1M
Q2 25
$1.2B
$616.2M
Q1 25
$1.0B
$891.5M
Q4 24
$913.1M
$858.9M
Q3 24
$845.2M
$813.0M
Q2 24
$957.9M
$691.7M
Q1 24
$841.6M
$695.1M
Debt / Equity
BETR
BETR
HCAT
HCAT
Q4 25
0.62×
Q3 25
0.46×
Q2 25
0.44×
Q1 25
1.02×
Q4 24
1.05×
Q3 24
0.97×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BETR
BETR
HCAT
HCAT
Operating Cash FlowLast quarter
$-166.6M
$9.9M
Free Cash FlowOCF − Capex
$-167.8M
$9.6M
FCF MarginFCF / Revenue
-378.6%
12.9%
Capex IntensityCapex / Revenue
2.7%
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-277.9M
$-697.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BETR
BETR
HCAT
HCAT
Q4 25
$-166.6M
$9.9M
Q3 25
$4.2M
$-464.0K
Q2 25
$-56.3M
$-9.0M
Q1 25
$-57.2M
$280.0K
Q4 24
$-380.0M
$-3.5M
Q3 24
$-10.6M
$6.2M
Q2 24
$-220.6M
$1.6M
Q1 24
$-42.8M
$10.3M
Free Cash Flow
BETR
BETR
HCAT
HCAT
Q4 25
$-167.8M
$9.6M
Q3 25
$4.0M
$-719.0K
Q2 25
$-56.7M
$-9.2M
Q1 25
$-57.4M
$-390.0K
Q4 24
$-383.4M
$-3.9M
Q3 24
$-11.7M
$5.5M
Q2 24
$-221.8M
$1.3M
Q1 24
$-43.3M
$10.1M
FCF Margin
BETR
BETR
HCAT
HCAT
Q4 25
-378.6%
12.9%
Q3 25
9.1%
-0.9%
Q2 25
-128.5%
-11.4%
Q1 25
-176.3%
-0.5%
Q4 24
-1534.6%
-4.9%
Q3 24
-40.5%
7.2%
Q2 24
-687.6%
1.7%
Q1 24
-194.5%
13.5%
Capex Intensity
BETR
BETR
HCAT
HCAT
Q4 25
2.7%
0.4%
Q3 25
0.5%
0.3%
Q2 25
0.9%
0.3%
Q1 25
0.6%
0.8%
Q4 24
13.6%
0.5%
Q3 24
4.1%
0.9%
Q2 24
3.9%
0.4%
Q1 24
2.1%
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BETR
BETR

Segment breakdown not available.

HCAT
HCAT

Recurring Technology$51.9M69%
Professional Services$22.8M31%

Related Comparisons